Clinical Trial Detail

NCT ID NCT02399137
Title A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors Merrimack Pharmaceuticals
Indications

pancreatic adenocarcinoma

Therapies

nab-paclitaxel

Gemcitabine

MM-141

Age Groups: adult

No variant requirements are available.